Novartis has re-shaped itself as a pure-play innovative-medicines company, betting on the complement (iptacopan) and radioligand-therapy platforms after divesting Sandoz. Its rare-renal and complement franchise overlaps directly with AXLRx's PNH and IgA nephropathy coverage.
United States — Fabhalta covered via specialty pharmacy; complement franchise leverages the Soliris/Ultomiris access precedent.
United Kingdom — NICE appraisals ongoing; Cosentyx and Kisqali NHS-commissioned.
GCC (Gulf) — SFDA registration underway for the complement portfolio; oncology assets exposed to Gulf tender dynamics.
Iptacopan oral pivot versus the anti-C5 IV class. Orphan-drug exclusion from IRA negotiation (US), NICE HST (UK) and SFDA lag (GCC).
PNH diagnosis pathway, FLAER flow-cytometry bottleneck and the treated-prevalent pool across US centres.
Why the orphan-drug exclusion shields anti-C5 agents from IRA negotiation, ICER's 2024 value verdict on iptacopan, and Part B vs Part D routing.
SCD epidemiology, genotype mix, VOC and organ-damage burden, and the 22-year life-expectancy gap across the US in-market population.
Gene-therapy access at $2.2–3.1M, the CMS Cell & Gene Therapy Access Model, VOC-freedom endpoints, and the hydroxyurea step-edit.
Two Dec-2023 gene therapies (Casgevy, Lyfgenia) reset a ~100,000-patient market, while voxelotor's 2024 withdrawal thins the oral field.
Only ribociclib has posted consistent overall-survival wins in the three-way first-line CDK4/6 contest. MONALEESA-2 showed 63.9 versus 51.4 months (HR 0.76). The real competition has moved downstream, where 2023 approvals of an oral SERD and an AKT inhibitor carve the post-CDK4/6 line by biomarker.
2023 · Acquisition — Chinook Therapeutics ($3.2B) · IgA nephropathy
2024 · Acquisition — MorphoSys ($2.9B) · Myelofibrosis
2023 — Fabhalta (iptacopan) FDA approval in PNH · First oral monotherapy challenging the Alexion C5 duopoly
2023 — Sandoz spin-off completed · Full pivot to innovative medicines